Abstract: This invention is a method to predict the motor response of presumptive negotiators after simulated decision challenges through measurement of glutamate/GABA ratios in spectral MRI (MRS) of the negotiators. The sampled voxels of MRS include precentral gyrus speech (larynx) and writing (hand) areas and/or supplementary motor cortex. The glutamate/GABA ratio or excitation/inhibition (E/I) ratio is predicted to be U shaped where an elevated E/I ratio is predicted to be impulsive decision-making and lower E/I ratio is predicted to be indecisiveness. This method may aid in the screening of negotiators who may be best suited for resolution of impasse conflicts.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: This invention is a safe and effective method to treat chronic pain with the oral administration of procaine as a non-selective voltage sodium channel (VGSC) blocker. The dose of oral procaine has been estimated based upon the pharmacokinetics required to produce action potential inhibition in neurons of dorsal root ganglia. Intraneural ion trapping effects and low CSF pseudocholinesterase will increase the concentration of charged procaine within Nav 1.8 channels. The co-administration of benzodiazepines will increase the therapeutic ratio of procaine mitigating central nervous system toxicity. A dibucaine number is required prior to initiation of therapy. Side effects have hindered development of selective VGSC blockers. Modification of oral procaine administration with over 100 clinical practice years of known side effects may meet this unmet need.

Abstract: Parkinson's disease is characterized by degeneration of highly metabolic dopaminergic neurons which produce clinical signs to include tremor, rigidity, and glabellar reflex. There are few objective, inexpensive, sensitive, and specific tests for early diagnosis of Parkinson's disease. In this invention, patients who manifest early objective signs of possible Parkinson's disease are pretreated with a supplement to increase central nervous system NAD+, and then subsequently administered a sodium L-lactate infusion after which the signs of early Parkinson's disease are recorded. Remission of the early signs of Parkinson's disease is diagnostic for Parkinson's disease. A clinical trial is suggested.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: This invention describes the potential benefits of chronic oral administration of triethyl citrate (TEC) for the treatment of Alzheimer's disease and atherosclerosis. Evidence is presented that TEC crosses the blood brain barrier via passive diffusion, and the pharmacologic properties of TEC are distinct from administration of citrate salts. Further clinical trials in animal and human subjects is encouraged.

Abstract: The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: This invention describes an affordable, renewable, sustainable (ARS) system to produce electricity, comprising a zinc air fuel cell (ZAFC) and photovoltaic cell. This ZAFC produces electricity operating in the pH range of 6.5-8.5 such that the primary waste species in the electrolyte are zinc cations of Zn+2 and ZnOH+. These cations are reduced by electrons from photovoltaic cells, and this ZAFC is easily rechargeable with a photovoltaic cell, and it can be overcharged. Also the electrolyte can be separated from the cell, and plating with photo reduction of zinc occurs rapidly on graphite, copper, or zinc cathodes. The efficiency of the ZAFC is approximately 58%, plus the added efficiency of reclaimed reduced zinc cations to zinc, either through recharging or plating. The electrolyte can be seawater or saline. The raw materials for this ZAFC are sufficiently available such that this system could provide ARS electricity.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: Methods of identifying agents that modulate the interleukin-17 (IL-17) pathway are described. Said methods use detecting a level of granulocyte colony-stimulating factor (G-CSF) in a cell supernatant and/or detecting an expression level of one gene or a panel of genes of a cell treated with an agent. Also described are probes capable of detecting a gene or panel of genes and kits for identifying agents that modulate the IL-17 pathway.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: Hyperscanning, the simultaneous measurement of brain activity among dyads or groups, has shown synchrony measured by fMRI, EEG, MEG, and fNIRS. This synchrony is evident during cooperative decision-making, but the underlying mechanism has not been elucidated. At minimum, in order for synchrony to occur, systems must oscillate and share information. Through the skin effect, changing magnetic fields permeate the human central nervous system, can share information from dyads and groups, and can synchronize oscillating oxygen reduction reactions (ORR) in the mitochondria. In vitro evidence has shown that ORR can be influenced ?-m tesla, extremely low frequency magnetic fields without producing thermal or ionization effects. Ascertaining the unique characteristics of such magnetic fields that can produce interbrain synchrony is a daunting task; however, this discovery could benefit impasse conflict negotiations.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: Methods to measure free IL-17 in a sample comprising IL-17 and a small molecule modulator of IL-17.

Abstract: This invention describes a sustainable, renewable, and inexpensive process to produce electrical energy with zinc air fuel cells (ZAFC) not comprised of a corrosive alkaline electrolyte. The cell's zinc hydroxide waste product is reduced to zinc metal by heat from carbothermal solar concentration. Further research to improve the efficiency of the electrode design and improve zinc oxide reduction is encouraged. The benefits of ZAFC as a primary source of electricity to include underdeveloped countries is discussed.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Hypermetabolic states that include cancer, infections, inflammations, mental illnesses, and chronic pain are sustained with ATP produced by aerobic glycolysis. Because of redundancies within this metabolic pathway, inhibition of aerobic glycolysis requires a combination drug therapy, which at the present time is optimal with 2-Deoxy-D-Glucose (2DG) and D-Lactic Acid Dimer (DLAD). Red blood cells exclusively derive energy from aerobic glycolysis, and spectrophotometric measurement of hemolysis can be utilized to monitor the effectiveness of drug combinations that inhibit aerobic glycolysis, particularly in hypermetabolic states. These measurements can be performed cheaply and easily in most health care facilities. Complete inhibition of aerobic glycolysis may necessitate red blood cell transfusion, but cells with mitochondria can produce sufficient ATP through lipid oxidation and amino acid metabolism to remain viable.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Perennial grasses can be a source of sustainable and renewable food supplies. Unlike efforts in selective genetics to produce grains with perennial phenotypes, this invention processes perennial grasses that can be efficiently and economically extracted to produce an easily stored food that does not require refrigeration. Grasses are cut, juice is extracted, centrifuged, treated with non-activated coconut charcoal, filtered , microscopically examined to assure minimal cellulose content, and dehydrated to produce a stable solid that can be rehydrated or incorporated into flours. Yields from fresh grass extraction exceeds those from rehydration of hay. Non-activated coconut charcoal is a renewable and inexpensive resource. Perennial pasture grasses grown with clover or other legumes require minimal yearly fertilization. This process can be sustainable in societies without electricity.